Anixa Biosciences Inc (ANIX) Stock Price, Quote & News

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 708 9808

Website: www.anixa.com

Address:

3150 Almaden Expressway, Suite 250, San Jose, United States

TrendWitcher Aug. 23 at 5:39 AM

$ANIX Anixa Biosciences is a cancer therapy developer with early stage programs and funding requirements

1 · Reply

bioinvestorrr Aug. 20 at 1:02 PM

$ANIX insane how this is still 3$

1 · Reply

BigSqueezeComing Aug. 20 at 12:42 PM

$ANIX This is part of a string of allowances (U.S., Canada, now China). A strong global IP portfolio signals serious commercialization potential.

2 · Reply

BigSqueezeComing Aug. 20 at 12:41 PM

$ANIX Patent Strength in China: China has one of the largest breast cancer patient populations in the world. Securing patent protection there opens the door to future regulatory filings, licensing, or partnerships in a major market.

0 · Reply

BigSqueezeComing Aug. 20 at 12:40 PM

$ANIX On August 20, 2025, Anixa Biosciences received a Notice of Allowance from the Chinese National Intellectual Property Administration (CNIPA) for a new patent covering its breast cancer vaccine technology (licensed from Cleveland Clinic). This marks the first Chinese patent granted for that vaccine and extends intellectual property protection in China into at least the 2040s.

0 · Reply

BigSqueezeComing Aug. 20 at 12:40 PM

$ANIX loading up

0 · Reply

BigSqueezeComing Aug. 20 at 12:39 PM

$ANIX Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology By PR Newswire | August 20, 2025, 8:37 AM

0 · Reply

JarvisFlow Aug. 19 at 12:00 PM

D. Boral Capital updates rating for Anixa Biosciences ( $ANIX ) to Buy, target set at 10.

0 · Reply

Thestocktraderhubzee Aug. 18 at 1:12 PM

$ANIX Anixa Biosciences Announces Second Patient In Fourth Dose Cohort Treated In Ongoing Phase 1 Clinical Trial Evaluating Chimeric Antigen Receptor-T Cell Therapy For Recurrent Ovarian Cancer

0 · Reply

justiceforb_85 Aug. 17 at 1:10 AM

$ANIX the preclinical evidence for targeting alpha lactalbumin in TNBC is compelling. I look forward to the updated clinical data in P1.

0 · Reply

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:37 AM EDT - 6 days ago

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Aug 18, 2025, 9:00 AM EDT - 8 days ago

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Aug 12, 2025, 8:05 AM EDT - 14 days ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Aug 8, 2025, 9:15 AM EDT - 18 days ago

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Aug 4, 2025, 8:45 AM EDT - 22 days ago

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Jul 30, 2025, 8:15 AM EDT - 27 days ago

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Jul 24, 2025, 8:00 AM EDT - 4 weeks ago

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Jul 15, 2025, 3:49 PM EDT - 6 weeks ago

Anixa Biosciences: Oncology Platform With Asymmetric Upside

Jul 9, 2025, 8:00 AM EDT - 6 weeks ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jun 23, 2025, 8:00 AM EDT - 2 months ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 20, 2025, 7:30 AM EDT - 2 months ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 10, 2025, 7:00 AM EDT - 2 months ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 9, 2025, 8:00 AM EDT - 2 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Jun 3, 2025, 7:25 AM EDT - 3 months ago

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Jun 2, 2025, 7:00 AM EDT - 3 months ago

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

May 19, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

May 12, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 30, 2025, 8:00 AM EDT - 4 months ago

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Apr 14, 2025, 8:00 AM EDT - 4 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Apr 9, 2025, 8:00 AM EDT - 4 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Apr 1, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Mar 25, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Mar 24, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Mar 17, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Mar 10, 2025, 8:30 AM EDT - 6 months ago

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Mar 3, 2025, 8:00 AM EST - 6 months ago

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Feb 26, 2025, 8:00 AM EST - 6 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Feb 25, 2025, 7:30 AM EST - 6 months ago

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Feb 24, 2025, 8:00 AM EST - 6 months ago

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Feb 18, 2025, 8:00 AM EST - 6 months ago

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Feb 14, 2025, 7:00 AM EST - 6 months ago

Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

Feb 11, 2025, 8:30 AM EST - 7 months ago

Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum

Feb 4, 2025, 8:30 AM EST - 7 months ago

Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention

Jan 21, 2025, 8:30 AM EST - 7 months ago

Anixa Biosciences CEO Provides Letter to Shareholders

Dec 4, 2024, 8:30 AM EST - 9 months ago

Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10

Nov 22, 2024, 8:15 AM EST - 9 months ago

Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 8:20 AM EST - 10 months ago

Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Nov 8, 2024, 1:17 PM EST - 10 months ago

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 6, 2024, 8:30 AM EST - 10 months ago

Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 31, 2024, 8:15 AM EDT - 10 months ago

Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024

Oct 28, 2024, 8:30 AM EDT - 10 months ago

Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 15, 2024, 9:00 AM EDT - 11 months ago

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Oct 7, 2024, 8:30 AM EDT - 11 months ago

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Sep 30, 2024, 8:30 AM EDT - 11 months ago

Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium

Aug 26, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Jul 29, 2024, 8:45 AM EDT - 1 year ago

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting

TrendWitcher Aug. 23 at 5:39 AM

$ANIX Anixa Biosciences is a cancer therapy developer with early stage programs and funding requirements

1 · Reply

bioinvestorrr Aug. 20 at 1:02 PM

$ANIX insane how this is still 3$

1 · Reply

BigSqueezeComing Aug. 20 at 12:42 PM

$ANIX This is part of a string of allowances (U.S., Canada, now China). A strong global IP portfolio signals serious commercialization potential.

2 · Reply

BigSqueezeComing Aug. 20 at 12:41 PM

0 · Reply

BigSqueezeComing Aug. 20 at 12:40 PM

0 · Reply

BigSqueezeComing Aug. 20 at 12:40 PM

$ANIX loading up

0 · Reply

BigSqueezeComing Aug. 20 at 12:39 PM

0 · Reply

JarvisFlow Aug. 19 at 12:00 PM

D. Boral Capital updates rating for Anixa Biosciences ( $ANIX ) to Buy, target set at 10.

0 · Reply

Thestocktraderhubzee Aug. 18 at 1:12 PM

$ANIX Anixa Biosciences Announces Second Patient In Fourth Dose Cohort Treated In Ongoing Phase 1 Clinical Trial Evaluating Chimeric Antigen Receptor-T Cell Therapy For Recurrent Ovarian Cancer

0 · Reply

justiceforb_85 Aug. 17 at 1:10 AM

$ANIX the preclinical evidence for targeting alpha lactalbumin in TNBC is compelling. I look forward to the updated clinical data in P1.

0 · Reply

Scientwist Aug. 15 at 3:25 AM

$ANIX Quietly loading.. FDA-approved Phase 2 breast cancer vaccine, ovarian CAR-T patents locked till 2045, and partnerships with Cleveland Clinic. No hype, low float, stealth setup. When this wakes up, it won’t ask permission. Sniper entry now, bragging rights later. #biotech #moonshot #convictionplay

1 · Reply

Lovelylatta Aug. 14 at 1:45 PM

$ANIX I have been watching this stock for over a year so I decided to take a chance and open a position.

0 · Reply

justiceforb_85 Aug. 13 at 3:11 AM

$ANIX when is the next clinical update?

1 · Reply

BigSqueezeComing Aug. 12 at 12:17 PM

$ANIX Extended IP Protection: Securing patent coverage through 2045 offers a long runway for commercialization and differentiation in the solid tumor CAR‑T space.

0 · Reply

BigSqueezeComing Aug. 12 at 12:17 PM

$ANIX pt 3.5

0 · Reply

BigSqueezeComing Aug. 12 at 12:17 PM

$ANIX Anixa recently received a new U.S. patent (No. 12,384,826)** covering its CAR-T (CER-T) platform designed for treating solid tumors, with patent protection now extended through 2045. The patent includes fundamental methods and compositions tied to the technology, enhancing long-term security around this field.

0 · Reply

BigSqueezeComing Aug. 12 at 12:15 PM

$ANIX Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology By PR Newswire | August 12, 2025, 8:05 AM

0 · Reply

stockobserver51 Aug. 9 at 2:31 PM

$ANIX Biodiad, from what I gathered from the last announcement, the Cleveland Clinic is participating in Phase 2, just as it was in Phase 1. Given the clinic's knowledge from Phase 1, this is only logical.

1 · Reply

Biodiad Aug. 8 at 10:00 PM

$ANIX But does that mean that Cleveland Clinic will not fund Phase 2? Is that on our dime now? Would affect cash burn significantly.

1 · Reply

JarvisFlow Aug. 5 at 12:00 PM

D. Boral Capital has adjusted their stance on Anixa Biosciences ( $ANIX ), setting the rating to Buy with a target price of 10.

0 · Reply

XkaliburTrading Aug. 5 at 11:49 AM

$ANIX https://newsfilter.io/articles/d-boral-capital-maintains-buy-on-anixa-biosciences-maintains-10-price-target-c188d0b0cef7c98f2640aeb64d1c6471

0 · Reply

bioinvestorrr Aug. 4 at 7:07 PM

$ANIX should be much higher imo

0 · Reply

Market Cap	96.63M
Revenue (ttm)	0.00
Net Income (ttm)	-12.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	50,700
Avg Vol	103,720
Day's Range	N/A - N/A
Shares Out	32.21M
Stochastic %K	41%
Beta	0.43
Analysts	Strong Sell
Price Target	$9.00